Published in Expert Rev Anticancer Ther on October 01, 2015
TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight (2016) 0.82
Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis. Oncotarget (2016) 0.75
Immunotherapy meets targeted therapy: will this team end the war against cancer? Transl Lung Cancer Res (2015) 0.75
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun (2017) 0.75
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Res (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
T cell exhaustion. Nat Immunol (2011) 11.08
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Melanoma. N Engl J Med (2006) 8.80
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther (2015) 2.21
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA (2014) 2.13
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist (2007) 1.93
Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 1.66
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res (2014) 1.54
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev (2014) 1.39
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 1.36
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int (2015) 1.25
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol (2015) 1.11
Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer (2011) 1.06
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res (2014) 1.03
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology (2014) 1.01
Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol (2015) 0.96
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene (2015) 0.91
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther (2014) 0.91
Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol (2012) 0.89
Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy (2011) 0.88
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res (2014) 0.81
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
Gauging the Long-Term Benefits of Ipilimumab in Melanoma. J Clin Oncol (2015) 0.80
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res (2015) 0.79
Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract (2011) 0.79
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol (2005) 1.03
Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol (2006) 1.02
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol (2004) 1.02
Melanoma exosomes: messengers of metastasis. Nat Med (2012) 0.96
Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res (2012) 0.95
Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther (2012) 0.89
Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother (2008) 0.87
Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother (2006) 0.86
Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Mol Cell Proteomics (2013) 0.85
Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther (2002) 0.83
Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells. Cancer Biol Ther (2006) 0.81
In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med (2011) 0.81
Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display. Cancer Res (2007) 0.80
Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother (2003) 0.80
Isolation of melanoma cell subpopulations using negative selection. Methods Mol Biol (2014) 0.79
Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. Int J Cancer (2010) 0.79
Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. Cancer Immunol Immunother (2005) 0.78
Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Melanoma Res (2016) 0.78
Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013. Pigment Cell Melanoma Res (2014) 0.77
Combination therapy of immunocytokines with ipilimumab: a cure for melanoma? J Invest Dermatol (2013) 0.76
Colon cancer antigen and anti-idiotype vaccines. Cancer Chemother Biol Response Modif (2003) 0.76
Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches. Oncoimmunology (2012) 0.75
Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice. J Immunol (2003) 0.75
Relapse of melanoma after successful adoptive T-cell therapy: escape through inflammation-induced phenotypic melanoma cell plasticity. Pigment Cell Melanoma Res (2013) 0.75